Screener
Viridian Therapeutics, Inc. VRDN Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Viridian Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s debt-to-equity?
- Viridian Therapeutics, Inc. (VRDN) reported debt-to-equity of 0.2× in Q2 2026.
- How has Viridian Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Viridian Therapeutics, Inc.'s debt-to-equity increased by 285.5% year-over-year, from 0× to 0.2×.
- What is the long-term trend for Viridian Therapeutics, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s debt-to-equity has grown at a 129.7% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Viridian Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude